Quarterly ResultAug 6, 2026, 04:21 PM
Artivion Q2 Revenue $125.8M; FDA Approves AMDS; Completes Endospan Acquisition
AI Summary
Artivion reported Q2 2026 revenue of $125.8 million, an 11% GAAP increase, and adjusted EBITDA of $26.4 million, up 7%. The company posted a GAAP net loss of $(13.5) million, compared to a net income of $1.3 million in Q2 2025. Key strategic milestones included U.S. FDA PMA approval for its AMDS Hybrid Prosthesis and the completion of the Endospan Ltd. acquisition, enhancing its aortic arch portfolio. Artivion reaffirmed its full-year 2026 revenue and adjusted EBITDA guidance.
Key Highlights
- U.S. FDA PMA Approval for AMDS Hybrid Prosthesis announced.
- Completed acquisition of Endospan Ltd. during the quarter.
- Q2 2026 revenue increased 11% to $125.8 million (9% constant currency).
- Q2 2026 GAAP net loss was $(13.5) million, or $(0.28) per share.
- Q2 2026 adjusted EBITDA increased 7% to $26.4 million.
- On-X product revenue grew 18% and stent grafts grew 12% (constant currency).
- Reaffirmed full-year 2026 revenue guidance of $480-$496 million.
- Reaffirmed full-year 2026 adjusted EBITDA guidance of $92-$99 million.
Price Impact
More from AORT